At Sinopep, we specialize in accelerating the discovery phase of peptide and oligonucleotide therapeutics. Our flexible, high-quality custom synthesis services provide researchers with reliable, cutting-edge materials tailored to early-stage needs—from target validation to lead optimization—empowering breakthrough discoveries and driving therapeutic innovation worldwide.

Sinopep supports drug discovery teams with integrated CMC-informed peptide and oligonucleotide services, enabling efficient progression from early research through preclinical development. Our discovery-driven approach helps de-risk programs and accelerate the transition to development-ready candidates.